MCID: BCL006
MIFTS: 65

B-Cell Lymphomas malady

Categories: Rare diseases, Genetic diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for B-Cell Lymphomas

Aliases & Descriptions for B-Cell Lymphomas:

Name: B-Cell Lymphomas 38 69
Lymphoma, B-Cell 50 24 29 42
B-Cell Lymphoma 12 50 14
B-Cell Lymphocytic Neoplasm 12
Lymphoma B-Cell 52

Classifications:



External Ids:

Disease Ontology 12 DOID:707
MeSH 42 D016393
NCIt 47 C27907 C3457
UMLS 69 C0079731

Summaries for B-Cell Lymphomas

NIH Rare Diseases : 50 b-cell lymphoma refers to types of non-hodgkin lymphoma that are characterized by abnormalities of the "b-cells" (a type of white blood cell that makes antibodies to help fight infection). the condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. when present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. the underlying cause of b-cell lymphoma is poorly understood. however, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and connective-tissue disorders. treatment is based on many factors, including the severity of the condition and the associated signs and symptoms. last updated: 1/10/2016

MalaCards based summary : B-Cell Lymphomas, also known as lymphoma, b-cell, is related to systemic mastocytosis and ectodermal dysplasia. An important gene associated with B-Cell Lymphomas is BCL6 (B-Cell CLL/Lymphoma 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Adcetris and Bexxar have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in B cells.

Related Diseases for B-Cell Lymphomas

Diseases in the B-Cell Lymphomas family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphomas via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 469)
id Related Disease Score Top Affiliating Genes
1 systemic mastocytosis 30.0 CD5 MALT1 PAX5
2 ectodermal dysplasia 28.7 BCL10 BCL2 BCL6 CCND1 CD5 FOXP1
3 diffuse large b-cell lymphoma 12.7
4 marginal zone b-cell lymphoma 12.5
5 t-cell/histiocyte rich large b cell lymphoma 12.3
6 primary mediastinal large b-cell lymphoma 12.3
7 alk-positive large b-cell lymphoma 12.3
8 primary cutaneous marginal zone b-cell lymphoma 12.3
9 nodal marginal zone b-cell lymphoma 12.3
10 intravascular large b-cell lymphoma 12.3
11 splenic diffuse red pulp small b-cell lymphoma 12.3
12 primary cutaneous diffuse large b-cell lymphoma, leg type 12.3
13 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 12.3
14 diffuse large b-cell lymphoma of the central nervous system 12.3
15 indolent b cell lymphoma 12.2
16 b-cell lymphoma of mucosa-associated lymphoid tissue 12.2
17 diffuse large b-cell lymphoma with chronic inflammation 12.1
18 high grade b-cell lymphoma with rearrangements of myc and bcl2 and/or bcl6 12.0
19 gray zone lymphoma 12.0
20 lymphoma, malt, somatic 12.0
21 plasmablastic lymphoma 11.7
22 splenic marginal zone lymphoma 11.6
23 mediastinal gray zone lymphoma 11.5
24 lymphomatoid granulomatosis 11.4
25 lymphoma 11.4
26 burkitt lymphoma 11.4
27 primary effusion lymphoma 11.3
28 immunotactoid glomerulopathy 11.3
29 thyroid lymphoma 11.3
30 mature b-cell neoplasm 11.1
31 reticulosarcoma 11.0
32 monoclonal gammopathy of uncertain significance 11.0
33 immunotactoid or fibrillary glomerulopathy 11.0
34 immunodeficiency 14 11.0
35 mediastinitis 10.7
36 primary central nervous system lymphoma 10.6
37 leukemia 10.5
38 hodgkin lymphoma 10.5
39 follicular lymphoma 10.4
40 hepatitis 10.4
41 rubella panencephalitis 10.4 BCL2 BCL6 MALT1
42 ichthyosis, congenital, autosomal recessive 10 10.4 BCL10 BCL2 BCL6
43 male infertility 10.4 BCL2 CCND1
44 brca1 and brca2 hereditary breast and ovarian cancer 10.4 BCL10 BCL6 MALT1
45 prader-willi syndrome due to paternal deletion of 15q11q13 type 1 10.4 BCL10 IRF4 MALT1
46 trigeminal nerve neoplasm 10.3 CD5 MME
47 prinzmetal's variant angina 10.3 BCL6 IRF4 MYC
48 parotitis 10.3 CCND1 CD5 MALT1
49 vaginal adenosarcoma 10.3 BCL2 MME TP53
50 ethmoid sinus inverted papilloma 10.3 BCL6 MME

Graphical network of the top 20 diseases related to B-Cell Lymphomas:



Diseases related to B-Cell Lymphomas

Symptoms & Phenotypes for B-Cell Lymphomas

MGI Mouse Phenotypes related to B-Cell Lymphomas:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 REL TNFRSF8 TP53 AICDA BCL10 BCL2
2 immune system MP:0005387 10.36 BCL6 CCND1 CCND3 CD5 CDKN1B IRF4
3 cellular MP:0005384 10.25 AICDA BCL10 BCL2 BCL6 CCND1 CDKN1B
4 endocrine/exocrine gland MP:0005379 10.16 BCL10 CCND3 CDKN1B MYC PRDM1 TNFRSF8
5 craniofacial MP:0005382 10.04 PRDM1 TP53 BCL2 CCND1 CDKN1B MYC
6 digestive/alimentary MP:0005381 10.02 AICDA BCL2 CCND1 CDKN1B MYC REL
7 integument MP:0010771 10.02 AICDA BCL2 CCND1 CD5 CDKN1B MME
8 neoplasm MP:0002006 9.96 AICDA BCL2 CCND1 CCND3 CDKN1B IRF4
9 liver/biliary system MP:0005370 9.92 BCL6 CCND3 CDKN1B MME MYC PRDM1
10 no phenotypic analysis MP:0003012 9.7 AICDA BCL6 CD5 CDKN1B MYC PRDM1
11 normal MP:0002873 9.65 AICDA BCL6 CCND1 CCND3 CD5 MYC
12 respiratory system MP:0005388 9.17 BCL2 BCL6 CCND1 CCND3 CDKN1B REL

Drugs & Therapeutics for B-Cell Lymphomas

FDA approved drugs:

(show all 9)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 46 BRENTUXIMAB VEDOTIN Seattle Genetics Approved August 2011
2
Bexxar 17 46 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa Approved June 2003
3
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
4
Mozobil 17 46 PLERIXAFOR Genzyme Approved December 2008
5
Revlimid 17 46 LENALIDOMIDE Celgene Approved June 2013
6
Rituxan 17 46 RITUXIMAB Biogen IDEC, Genentech Approved November 1997
7
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon Approved October 2008
8
Zevalin 17 46 IBRITUMOMAB TIUXETAN Biogen IDEC Approved February 2002
9
Zydelig 17 46 IDELALISIB Gilead Approved July 2014

Drugs for B-Cell Lymphomas (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 648)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
5
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
8
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1 9015-68-3
9
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
10
Idarubicin Approved Phase 4,Phase 3,Phase 2 58957-92-9 42890
11
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
12
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
13
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
14
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
15
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
16
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
19
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
20
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
21
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
22
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
23
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
24
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
25
Tenofovir Approved, Investigational Phase 4 147127-20-6 464205
26
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
27
Sofosbuvir Approved Phase 4,Phase 2 1190307-88-0 45375808
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
29
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
30
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1177-87-3
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Cortisol succinate Phase 4,Phase 3,Phase 2,Phase 1
43 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2,Phase 1
44 Hydrocortisone acetate Phase 4,Phase 3,Phase 2,Phase 1
45 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
46 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2295)
id Name Status NCT ID Phase
1 Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Unknown status NCT00429065 Phase 4
2 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
3 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4
4 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4
5 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4
6 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
7 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
8 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
9 Treatment of Diffuse Large B Cell Lymphoma Recruiting NCT01949818 Phase 4
10 Reduced Chemotherapy in Low Risk DLBCL Recruiting NCT02752815 Phase 4
11 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4
12 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Recruiting NCT02996617 Phase 4
13 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Recruiting NCT02585947 Phase 4
14 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
15 Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Active, not recruiting NCT02717949 Phase 4
16 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4
17 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma Not yet recruiting NCT02992834 Phase 4
18 Trial of GemOx±R Regimen in First-line Treatment of Elderly Aggressive B Cell Lymphoma Unknown status NCT01670370 Phase 3
19 Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Unknown status NCT00846157 Phase 3
20 Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma Unknown status NCT00499018 Phase 3
21 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
22 TREatment of degeNerative and Neoplastic Diseases With Rituximab Unknown status NCT01277172 Phase 2, Phase 3
23 Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R Unknown status NCT00322218 Phase 3
24 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3
25 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3
26 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
27 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3
28 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3
29 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
30 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3
31 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3
32 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
33 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
34 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
35 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3
36 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
37 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
38 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
39 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
40 Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma Unknown status NCT01570049 Phase 3
41 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3
42 Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma Unknown status NCT00091676 Phase 3
43 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma Unknown status NCT00003728 Phase 3
44 Efficacy of Tocilizumab in Primary Sjögren's Syndrome. Unknown status NCT01782235 Phase 2, Phase 3
45 Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia Unknown status NCT00764907 Phase 3
46 Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00707083 Phase 3
47 Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT01085617 Phase 3
48 Treatment of Mature B-cell Lymphoma/Leukaemia Completed NCT00162656 Phase 3
49 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3
50 Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) Completed NCT00147121 Phase 2, Phase 3

Search NIH Clinical Center for B-Cell Lymphomas

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Cell Lymphomas cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, b-cell

Genetic Tests for B-Cell Lymphomas

Genetic tests related to B-Cell Lymphomas:

id Genetic test Affiliating Genes
1 B-Cell Lymphoma 29
2 Lymphoma, B-Cell 24 BCL6

Anatomical Context for B-Cell Lymphomas

MalaCards organs/tissues related to B-Cell Lymphomas:

39
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Skin, Lung

Publications for B-Cell Lymphomas

Articles related to B-Cell Lymphomas:

(show top 50) (show all 3739)
id Title Authors Year
1
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. ( 28403071 )
2017
2
B-cell lymphomas involving Waldeyer's ring characterized by distinctive clinical and histopathological features: a comparison of pediatric to adult patients. ( 28086220 )
2017
3
Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. ( 27821509 )
2017
4
TET2 mutation in diffuse large B-cell lymphoma. ( 28331128 )
2017
5
B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells. ( 28351336 )
2017
6
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. ( 28041583 )
2017
7
Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. ( 27779774 )
2017
8
Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. ( 28103885 )
2017
9
Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma. ( 28057019 )
2017
10
Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. ( 28060891 )
2017
11
Impact of Double-Hit and Double-Expressor Phenotypes in Relapsed Aggressive B-Cell Lymphomas Treated With Autologous Hematopoietic Stem Cell Transplantation. ( 28034063 )
2017
12
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. ( 28055107 )
2017
13
3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro. ( 28054086 )
2017
14
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
15
ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature. ( 27740969 )
2017
16
LMP1 and LMP2A collaborate to promote Epstein-Barr virus (EBV)-induced B cell lymphomas in a cord blood-humanized mouse model but are not essential. ( 28077657 )
2017
17
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study. ( 28507339 )
2017
18
Performance of a Commercially Available MAL Antibody in the Diagnosis of Primary Mediastinal Large B-Cell Lymphoma. ( 27879516 )
2017
19
Cyclin A2 as a potential differential marker of splenic diffuse red pulp small B-cell lymphoma: a report of the first case. ( 27761608 )
2017
20
Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. ( 28058506 )
2017
21
Anaplastic lymphoma kinase positive large B-cell lymphoma: Literature review and report of an endoscopic fine needle aspiration case with tigroid backgrounds mimicking seminoma. ( 27686567 )
2017
22
Identification of distinct subgroups of EBV-positive post-transplant diffuse large B-cell lymphoma. ( 28059091 )
2017
23
FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation. ( 28090627 )
2017
24
Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation. ( 28069035 )
2017
25
Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas. ( 28395058 )
2017
26
Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for the treatment of diffuse large B-cell lymphoma and Burkitt lymphoma. ( 28385782 )
2017
27
Inflammatory Biomarkers in Diffuse Large B-Cell Lymphoma: Time for Extending the Established Prognosis Scores? ( 28076864 )
2017
28
Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas. ( 28072473 )
2017
29
Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). ( 28076329 )
2017
30
A Case of Therapy-Related Acute Leukemia With Mixed Phenotype With BCR-ABL1 After Treatment of Diffuse Large B-Cell Lymphoma. ( 28029006 )
2017
31
Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy. ( 28076862 )
2017
32
Calcitriol-mediated hypercalcemia in a patient with bilateral adrenal non-Hodgkin's B-cell lymphoma case report. ( 27124160 )
2016
33
Clinical implications of glutathione S-transferase genotyping in patients with diffuse large B-cell lymphoma. ( 28039708 )
2016
34
A case of intravascular large B cell lymphoma: New clinical and immunohistochemical findings. ( 27090763 )
2016
35
Evaluation of the diagnostic and prognostic value of PDL1-expression in Hodgkin- and B-cell lymphomas. ( 27045512 )
2016
36
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. ( 26585955 )
2016
37
Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma. ( 27077767 )
2016
38
Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in anA HIV-infected Man: A Case Report and ReviewA ofA the Literature. ( 27234438 )
2016
39
Diagnostic utility of SOX11 immunohistochemistry in differentiating cutaneous spread of mantle cell lymphoma from primary cutaneous B-cell lymphomas. ( 26762898 )
2016
40
Intravascular Large B-cell Lymphoma of the Bilateral Ovaries and Uterus in an Asymptomatic Patient with a t(11;22)(q23;q11) Constitutional Translocation. ( 27803414 )
2016
41
Identification of a novel stereotypic IGHV4-59/IGHJ5-encoded B-cell receptor subset expressed by various B-cell lymphomas with high affinity rheumatoid factor activity. ( 26858354 )
2016
42
Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. ( 27460179 )
2016
43
Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas. ( 27391453 )
2016
44
Alterations of miRNAs and miRNA-regulated mRNA expression in GC B cell lymphomas determined by integrative sequencing analysis. ( 27390358 )
2016
45
Novel IGH and MYC Translocation Partners in Diffuse Large B-Cell Lymphomas. ( 27356265 )
2016
46
Primary Mediastinal Large B-cell Lymphoma Exhibiting Endobronchial Involvement. ( 27803409 )
2016
47
Coexistent adrenal diffuse large B cell lymphoma in a patient with WaldenstrAPm's macrogloblinemia/lymphoplasmacytic lymphoma. ( 27365139 )
2016
48
Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma. ( 27187305 )
2016
49
Intravascular large B-cell lymphoma associated with silicone breast implant, HLA-DRB1*11:01, and HLA-DQB1*03:01 manifesting as macrophage activation syndrome and with severe neurological symptoms: a case report. ( 27634631 )
2016
50
Cauda equina syndrome due to large B-cell lymphoma: a case report. ( 26753799 )
2016

Variations for B-Cell Lymphomas

Cosmic variations for B-Cell Lymphomas:

9 (show all 22)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 3
2 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 3
3 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 3
4 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 3
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 3
6 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 3
7 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 3
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 3
9 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 3
10 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 3
11 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 3
12 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 3
13 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 3
14 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 3
15 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 3
16 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 3
17 COSM5274 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.484G>C p.D162H 1
18 COSM37029 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1937A>C p.Y646S 1
19 COSM37031 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1936T>A p.Y646N 1
20 COSM12475 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.238C>T p.R80* 1
21 COSM21829 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8138G>A p.R2713K 1
22 COSM22488 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8494C>T p.R2832C 1

Expression for B-Cell Lymphomas

Search GEO for disease gene expression data for B-Cell Lymphomas.

Pathways for B-Cell Lymphomas

Pathways related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 BCL10 BCL2 BCL6 CCND1 CDKN1B IRF4
2
Show member pathways
13.38 BCL2 BCL6 CCND1 IRF4 MYC TNFRSF8
3
Show member pathways
12.74 BCL10 CDKN1B MALT1 REL TP53
4 12.68 BCL2 CCND1 CDKN1B MYC TP53
5 12.58 BCL2 CCND1 CCND3 CDKN1B MYC TP53
6
Show member pathways
12.57 CCND1 CCND3 CDKN1B MYC TP53
7
Show member pathways
12.55 CCND1 CDKN1B MYC REL TP53
8 12.49 BCL2 CCND1 CDKN1B FOXP1 MYC TP53
9
Show member pathways
12.43 BCL10 IRF4 MALT1 REL
10 12.43 CCND1 CCND3 MYC TP53
11
Show member pathways
12.37 BCL2 CCND1 MYC TP53
12
Show member pathways
12.37 CCND1 CCND3 CDKN1B TP53
13
Show member pathways
12.37 CCND1 CCND3 CDKN1B MYC REL TP53
14
Show member pathways
12.36 CCND1 CCND3 CDKN1B MYC TP53
15 12.35 CCND1 CCND3 CDKN1B MYC TP53
16
Show member pathways
12.34 BCL10 BCL6 IRF4 MALT1 MYC REL
17
Show member pathways
12.31 CCND1 CDKN1B MYC TP53
18 12.3 BCL2 CDKN1B MYC TP53
19 12.28 CCND1 CCND3 CDKN1B REL TP53
20 12.25 AICDA BCL10 BCL6 IRF4 MALT1 PAX5
21 12.24 BCL10 BCL2 MALT1 MYC
22
Show member pathways
12.22 CCND1 CCND3 CDKN1B MYC
23
Show member pathways
12.21 BCL2 CCND1 CCND3 MYC
24
Show member pathways
12.17 CCND1 CCND3 CDKN1B MYC TP53
25 12.17 BCL6 CDKN1B MYC PAX5 REL TP53
26 12.15 BCL2 CCND1 MYC TP53
27 12.1 BCL2 CCND1 CDKN1B TP53
28
Show member pathways
12.09 CCND1 CDKN1B MYC TP53
29 12.07 BCL2 CCND1 CCND3 TP53
30 12.05 BCL2 BCL6 PRDM1 TP53
31 12 CCND1 CDKN1B MYC TP53
32 11.96 CCND1 CDKN1B MYC TP53
33 11.89 CD5 MME MS4A1
34 11.88 BCL10 BCL2 MALT1
35 11.86 BCL2 BCL6 CCND1 IRF4 MYC TP53
36 11.82 CCND1 CCND3 CDKN1B MYC TP53
37 11.78 BCL2 CCND1 CDKN1B MYC TP53
38 11.77 IRF4 MME MS4A1
39
Show member pathways
11.75 BCL2 REL TNFRSF8
40 11.75 CCND1 MYC TP53
41 11.75 CCND3 CDKN1B MYC
42 11.73 BCL6 PAX5 PRDM1
43 11.71 CCND3 CDKN1B MYC
44
Show member pathways
11.7 BCL2 CCND3 MYC
45 11.69 CCND1 CDKN1B MYC
46 11.69 BCL2 CCND1 CDKN1B MYC PAX5
47 11.66 AICDA BCL6 IRF4
48 11.63 BCL2 CCND1 CDKN1B MYC
49 11.56 BCL2 BCL6 CCND1 CCND3 CDKN1B MYC
50 11.55 CCND1 MYC TP53

GO Terms for B-Cell Lymphomas

Cellular components related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.89 AICDA BCL10 BCL2 BCL6 CCND1 CCND3
2 protein complex GO:0043234 9.73 BCL10 BCL2 CDKN1B MALT1 MYC TP53
3 nucleoplasm GO:0005654 9.44 BCL2 BCL6 CCND1 CCND3 CDKN1B FOXP1
4 CBM complex GO:0032449 9.16 BCL10 MALT1
5 cytoplasm GO:0005737 10.17 AICDA BCL10 BCL2 CCND1 CCND3 CDKN1B

Biological processes related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.93 BCL2 BCL6 CDKN1B TNFRSF8 TP53
2 regulation of cell proliferation GO:0042127 9.87 BCL6 CCND3 CDKN1B PRDM1
3 negative regulation of apoptotic process GO:0043066 9.8 BCL2 BCL6 CDKN1B MALT1 MYC TP53
4 cellular response to DNA damage stimulus GO:0006974 9.73 BCL2 BCL6 CCND1 MYC PARP9 TP53
5 B cell differentiation GO:0030183 9.72 AICDA BCL2 BCL6
6 humoral immune response GO:0006959 9.67 BCL2 MS4A1 PAX5
7 negative regulation of cell growth GO:0030308 9.67 BCL2 BCL6 CDKN1B TP53
8 positive regulation of cell cycle GO:0045787 9.63 CCND1 CDKN1B MYC
9 response to molecule of bacterial origin GO:0002237 9.6 BCL10 MALT1
10 replicative senescence GO:0090399 9.59 MME TP53
11 regulation of mitochondrial membrane permeability GO:0046902 9.58 BCL2 TP53
12 positive regulation of histone deacetylation GO:0031065 9.58 BCL6 TP53
13 response to gamma radiation GO:0010332 9.58 BCL2 MYC TP53
14 mitotic G1 DNA damage checkpoint GO:0031571 9.56 CCND1 TP53
15 regulation of apoptotic process GO:0042981 9.55 BCL10 BCL2 BCL6 MALT1 TP53
16 negative regulation of B cell apoptotic process GO:0002903 9.52 BCL6 FOXP1
17 response to fungus GO:0009620 9.51 BCL10 MALT1
18 regulation of T cell receptor signaling pathway GO:0050856 9.48 BCL10 MALT1
19 re-entry into mitotic cell cycle GO:0000320 9.43 CCND1 MYC
20 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.28 BCL6 CCND1 CCND3 MYC PARP9 PAX5
21 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.13 CCND1 CCND3 CDKN1B
22 transcription, DNA-templated GO:0006351 10.26 BCL6 CCND1 FOXP1 IRF4 MYC PAX5

Molecular functions related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.92 BCL6 FOXP1 IRF4 MYC PAX5 PRDM1
2 protein kinase binding GO:0019901 9.85 BCL10 CCND1 CCND3 CDKN1B TP53
3 sequence-specific DNA binding GO:0043565 9.8 BCL2 BCL6 FOXP1 IRF4 MYC PRDM1
4 protease binding GO:0002020 9.67 BCL10 BCL2 MALT1 TP53
5 protein phosphatase binding GO:0019903 9.65 BCL2 CDKN1B TP53
6 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.58 CCND1 CCND3 CDKN1B
7 kinase activator activity GO:0019209 9.43 BCL10 MALT1
8 transcription factor binding GO:0008134 9.43 BCL10 BCL2 CCND1 IRF4 MYC TP53
9 protein self-association GO:0043621 8.92 BCL10 FOXP1 MALT1 TP53
10 protein binding GO:0005515 10.13 AICDA BCL10 BCL2 BCL6 CCND1 CCND3

Sources for B-Cell Lymphomas

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....